ClinicalTrials.gg
RecruitingNCT07442812TKAUpdated Sep 1, 2026

Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty

An observational study in Knee Osteoarthritis, Gonarthrosis; Primary and Total Knee Arthroplasty, sponsored by Haseki Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Haseki Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Osteoarthritis, Knee with a site in Turkey — 52 open to participants now, 63 under way, 3 of them phase 3. Osteoarthritis, Knee · Turkey.

Planned enrollment
3rd of 70
270 · median 84
Started
2026
with 37 others
Observational
70 of 268
20 open now
Primary completion
2027-10
later than 58 of 62 live
Registered
224th of 268
by date

Among the 268 studies in Osteoarthritis, Knee with a site in Turkey, this one is the 3rd largest by planned enrollment of the 70 observational ones that give a count, is one of 38 that started in 2026, is one of 70 observational ones, reaches primary completion later than 58 of the 62 other live ones, and was the 224th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

52 of the 268 studies in Osteoarthritis, Knee with a site in Turkey are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Osteoarthritis, Knee with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.

The primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV).

Group allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.

Read the detailed description

Total knee arthroplasty (TKA) is an effective treatment for advanced knee osteoarthritis; however, early postoperative recovery may be influenced by pain severity, limited functional mobility, systemic inflammatory response, metabolic alterations, and postoperative nausea and vomiting. Optimization of perioperative medical management is therefore a key component of enhanced recovery pathways.

Dexamethasone is frequently incorporated into perioperative care due to its anti-inflammatory, analgesic, antiemetic, and metabolic effects. Despite widespread use, variability persists in routine clinical practice regarding route of administration and dosing strategies. Comparative real-world data evaluating oral and intravenous administration within standardized care pathways remain limited.

This study is designed as a single-center, prospective observational cohort investigation evaluating early postoperative recovery parameters associated with routine perioperative dexamethasone strategies. The study does not introduce experimental interventions, randomization, or alterations to established treatment protocols.

Participants are assigned to cohorts according to the routine perioperative management approach of the operating surgeon selected by the patient. Each participating surgeon follows a predefined dexamethasone protocol that was implemented prior to initiation of this study. Treatment allocation is therefore independent of the research process and reflects real-world clinical practice.

The exposure of interest is perioperative dexamethasone administration as part of routine clinical care. Exposure status is defined according to the route of administration applied within the surgeon's established perioperative protocol: intravenous dexamethasone, oral dexamethasone, or no dexamethasone.

The standard institutional regimens consist of 8 mg administered preoperatively and 4 mg administered on postoperative day one, delivered either intravenously or orally depending on routine practice. Patients receiving no dexamethasone serve as the comparison cohort. Exposure classification is determined prior to postoperative outcome assessment.

All surgical procedures are performed using standardized institutional techniques for primary total knee arthroplasty. Postoperative management follows a multimodal analgesic protocol consistent across cohorts. Rescue opioid administration is provided when clinically indicated, and cumulative tramadol dose is recorded. Laboratory monitoring and clinical assessments are performed according to routine perioperative care standards.

Outcome data are collected prospectively using standardized and validated measurement tools during the early postoperative period. Baseline demographic and clinical variables are documented to account for potential confounding factors. Statistical analyses will include appropriate parametric or non-parametric tests depending on distributional assumptions. Repeated measurements will be evaluated using repeated-measures analysis or mixed-effects modeling, with multivariable adjustment to account for baseline differences between cohorts. Statistical significance is defined as p \< 0.05.

The study is conducted in accordance with the Declaration of Helsinki and has received institutional ethics committee approval. All participants provide written informed consent prior to enrollment. Participation does not alter standard clinical management.

03

Conditions studied

  • Knee Osteoarthritis
  • Gonarthrosis; Primary
  • Total Knee Arthroplasty

Keywords

  • Total Knee Arthroplasty
  • Intravenous Dexamethasone
  • Knee Osteoarthritis
  • Gonarthrosis
  • Multimodal Analgesia
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients aged 50 to 80 years with a diagnosis of primary knee osteoarthritis who are scheduled to undergo elective primary total knee arthroplasty at Istanbul Sultangazi Haseki Training and Research Hospital. Eligible participants have an ASA physical status of I or II and are able to ambulate independently prior to surgery. All participants are capable of understanding the study procedures and providing written informed consent.

Patients are managed according to the routine perioperative dexamethasone protocols of the surgeon selected by the patient. Group allocation is based on the standard clinical practice of the chosen surgeon and not assigned by the investigators. Participants are followed prospectively to evaluate postoperative pain, inflammatory response, functional mobility, postoperative nausea and vomiting, and analgesic requirements during the early postoperative period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 50 and 80 years
  • Diagnosis of primary knee osteoarthritis (primary gonarthrosis)
  • Scheduled for elective primary total knee arthroplasty
  • I or II
  • Ability to ambulate independently (with or without assistive devices) preoperatively
  • Ability to understand study procedures and complete pain and functional assessments
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Revision total knee arthroplasty
  • History of knee joint infection
  • Inflammatory arthritis (e.g., rheumatoid arthritis)
  • Chronic systemic use
  • Uncontrolled diabetes mellitus
  • Known endocrine disorders affecting glucose metabolism
  • Active infection at any site
  • Known to corticosteroids
  • Severe hepatic, renal, or cardiac disease
  • Neurological or musculoskeletal disorders affecting gait or balance
  • Inability or unwillingness to comply with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intravenous Dexamethasone Group

    Patients undergoing primary total knee arthroplasty who receive dexamethasone intravenously according to the routine perioperative protocol of the operating surgeon (8 mg IV preoperatively and 4 mg IV postoperatively).

    Other: Routine perioperative management

  • Oral Dexamethasone Group

    Patients undergoing primary total knee arthroplasty who receive dexamethasone orally according to the routine perioperative protocol of the operating surgeon (8 mg oral preoperatively and 4 mg oral postoperatively).

    Other: Routine perioperative management

  • Control Group (No Dexamethasone)

    Patients undergoing primary total knee arthroplasty who do not receive dexamethasone as part of the routine perioperative management.

    Other: Routine perioperative management

Interventions

  • OtherRoutine perioperative management

    This is a prospective observational cohort study. No intervention is assigned by the investigators. Patients are managed according to the routine perioperative dexamethasone protocols of the surgeon chosen by the patient. One cohort receives intravenous dexamethasone (8 mg preoperatively and 4 mg postoperatively), one cohort receives oral dexamethasone (8 mg preoperatively and 4 mg postoperatively), and a control cohort receives no dexamethasone. All other perioperative and postoperative treatments are provided according to standard institutional practice and are not influenced by study participation.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Measured with Visiual Analog Scale (VAS)

    Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS), a validated 0 to 10 numeric rating scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity and therefore a worse outcome. Pain will be evaluated both at rest and during ambulation.

    Time frame: Measuring once in the preoperative period and every 6 hours during the first 48 hours after surgery.

  2. Functional Mobility (Timed Up and Go Test)

    Functional mobility will be evaluated using the Timed Up and Go (TUG) test, which measures the time (in seconds) required for a participant to stand up from a seated position, walk three meters, turn, walk back, and sit down. Shorter completion times indicate better functional mobility, whereas longer times indicate poorer performance.

    Time frame: Preoperatively and daily during the first 2 postoperative days.

  3. Nausea and Vomiting (PONV) Score

    Severity of postoperative nausea and vomiting will be assessed using a 0 to 10 Numeric Rating Scale (NRS), where 0 indicates no symptoms and 10 indicates the most severe nausea or vomiting imaginable. Higher scores represent worse symptoms.

    Time frame: Assessed daily during the first 2 postoperative days.

  4. Postoperative Opioid Requirement

    Requirement for rescue opioid analgesia following routine postoperative analgesic protocol consisting of scheduled paracetamol (4 doses per day) and NSAIDs (2 doses per day). Total opioid consumption and proportion of patients requiring opioid analgesia will be recorded. Cumulative tramadol dose administered as rescue analgesia will be recorded in milligrams (mg) during the first 48 hours after surgery. Higher values indicate greater postoperative analgesic requirement.

    Time frame: During the first 48 hours after surgery.

Secondary outcomes

  1. White Blood Cell Count

    Systemic inflammatory response will be assessed by measuring white blood cell (WBC) count, expressed in ×10³/µL. Higher values indicate greater inflammatory response.

    Time frame: Preoperatively and daily during the first 2 postoperative days.

  2. C-Reactive Protein Level

    ystemic inflammatory response will also be assessed by measuring C-reactive protein (CRP) levels, expressed in mg/L. Higher values indicate greater inflammatory response.

    Time frame: Preoperatively and daily during the first 2 postoperative days.

  3. Postoperative Glycemic Response

    Serum blood glucose levels will be measured in mg/dL using standard hospital laboratory methods. Daily postoperative values will be recorded to evaluate metabolic response and potential dexamethasone-associated hyperglycemia. Higher values indicate increased glycemic response.

    Time frame: Preoperatively and daily during the first 2 postoperative days.

  4. Knee Range of Motion - Flexion and Extension Angles

    Knee range of motion will be measured in degrees (°) using a standard universal goniometer aligned with anatomical landmarks (greater trochanter, lateral femoral epicondyle, and lateral malleolus). Measurements will be performed by trained personnel following a standardized protocol to minimize inter-observer variability. Greater flexion angles indicate improved joint mobility, whereas higher extension deficit values indicate reduced extension capacity.

    Time frame: Preoperatively and daily during the first 2 postoperative days.

  5. Postoperative Mobilization Status

    Postoperative mobilization status will be assessed using a categorical (ordinal) scoring system at postoperative day 0, day 1, and day 2. Patients will be classified into three categories based on their level of mobilization: 0 = Immobilized (no mobilization) 1. = Independently mobilized (without assistance) 2. = Assisted mobilization (with support) This classification is used to describe functional recovery status. Independent mobilization (score 1) represents the best functional outcome, assisted mobilization (score 2) represents moderate recovery, and immobilization (score 0) represents the poorest outcome. All patient groups (intravenous dexamethasone, oral dexamethasone, and control) will be evaluated daily using this scale.

    Time frame: Postoperative Day 0, Day 1, and Day 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen J, He Y, Deng T, Li Y, Wang X, Zhao M, Li F, Wang C, Tian H. Effects of Dexamethasone on Nausea, Vomiting, and Inflammatory Indexes After Total Knee Arthroplasty. Orthop Surg. 2025 Oct;17(10):2862-2868. doi: 10.1111/os.70139. Epub 2025 Aug 13. PubMed 40803755 ↗
  • De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011 Sep;115(3):575-88. doi: 10.1097/ALN.0b013e31822a24c2. PubMed 21799397 ↗
  • Liang S, Xing M, Jiang S, Zou W. Effect of Intravenous Dexamethasone on Postoperative Pain in Patients Undergoing Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. Pain Physician. 2022 Mar;25(2):E169-E183. PubMed 35322969 ↗
  • Xu B, Ma J, Huang Q, Huang ZY, Zhang SY, Pei FX. Two doses of low-dose perioperative dexamethasone improve the clinical outcome after total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2018 May;26(5):1549-1556. doi: 10.1007/s00167-017-4506-x. Epub 2017 May 4. PubMed 28474088 ↗
  • Chan TCW, Cheung CW, Wong SSC, Chung AYF, Irwin MG, Chan PK, Fu H, Yan CH, Chiu KY. Preoperative dexamethasone for pain relief after total knee arthroplasty: A randomised controlled trial. Eur J Anaesthesiol. 2020 Dec;37(12):1157-1167. doi: 10.1097/EJA.0000000000001372. PubMed 33105245 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional policies, patient privacy considerations, and the observational nature of this single-center study. The collected data are intended solely for the purposes of this research and related academic publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 179 non-industry observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 19 months is below that.

Counting every sponsor, half of 220 studies reached it within 24 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Mar 2, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442812
Lead sponsor
Haseki Training and Research Hospital
Responsible party
Mehmet Ersin (Associate Professor of Orthopaedics and Traumatology, Haseki Training and Research Hospital) — Principal investigator
First posted
Mar 2, 2026
Start date
Mar 31, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Atahan Eryilmaz, Resident Physician
Contact
dratahaneryilmaz@gmail.com
+90 552 609 9055
Mehmet Ersin, Associate Professor
Contact
drmehmetersin@gmail.com
+90 507 788 60 54
Mehmet Ersin, Associate Professor
principal investigator · Sultangazi Haseki Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion